Research Analysts Issue Forecasts for Invivyd Q1 Earnings

Invivyd, Inc. (NASDAQ:IVVD) – Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Invivyd in a note issued to investors on Tuesday, May 19th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Invivyd’s Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.05) EPS.

Several other analysts have also issued reports on IVVD. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research report on Wednesday, April 29th. BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a report on Monday. Finally, Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Invivyd presently has a consensus rating of “Hold” and an average target price of $8.00.

Invivyd Stock Performance

IVVD opened at $1.04 on Wednesday. The firm has a market cap of $306.39 million, a P/E ratio of -3.35 and a beta of 0.71. Invivyd has a 52-week low of $0.48 and a 52-week high of $3.07. The business’s fifty day moving average is $1.49 and its 200-day moving average is $1.89.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The business had revenue of $13.74 million for the quarter, compared to the consensus estimate of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in shares of Invivyd by 152.9% during the first quarter. Bank of America Corp DE now owns 962,386 shares of the company’s stock worth $1,251,000 after purchasing an additional 581,782 shares during the period. Stempoint Capital LP lifted its position in shares of Invivyd by 89.4% during the first quarter. Stempoint Capital LP now owns 1,874,546 shares of the company’s stock valued at $2,437,000 after purchasing an additional 884,724 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Invivyd by 1.7% during the 1st quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock worth $42,857,000 after buying an additional 551,188 shares in the last quarter. Eversept Partners LP lifted its holdings in Invivyd by 6.4% during the first quarter. Eversept Partners LP now owns 2,276,349 shares of the company’s stock worth $2,959,000 after acquiring an additional 136,219 shares during the period. Finally, SummitTX Capital L.P. purchased a new position in shares of Invivyd in the 1st quarter worth about $37,000. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.